Ribosomal protein L23a pseudogene 73 (RPL23AP73)

Ribosomal protein L23a pseudogene 73 (RPL23AP73) is classified as a **processed pseudogene** in the human genome[2][8][7]. It does not code for a functional protein, distinguishing it from its parent gene RPL23A, which encodes a structural component of the ribosome's large (60S) subunit[1][7]. RPL23AP73 has no known biological function, disease associations, or role as a therapeutic target. There is no evidence that it encodes a protein, nor that it is directly involved in biological pathways, pharmacology, or disease mechanisms. No drugs are known to interact with it, and there is no established mechanism of action, biomarker status, or reported safety concerns regarding this pseudogene. **Note:** There are many ribosomal protein L23a pseudogenes in the human genome (designated *RPL23AP1* to *RPL23AP97* and others), but these are nonfunctional “copies” and not drug targets. Functional and disease-association data (such as in cancer or autoimmune disease) apply to the parental RPL23A gene or certain expressed pseudogenes (e.g., RPL23AP53), not RPL23AP73 itself[3][5][9]. Given its pseudogene status and lack of evidence for protein coding or disease relevance, RPL23AP73 should not be considered a therapeutic target, and there is nothing indicating it is a receptor, enzyme, transporter, or other molecular target class[1][2][7][8].

Other names

RPL23A_36_1508